天壇生物(600161.SH):僅為相關血漿療法提供設備及技術等支持 不會對公司主營業務產生影響
格隆匯2月16日丨天壇生物(600161.SH)公佈,近日,公司關注到相關媒體報道,現將有關情況説明如下:
一、媒體報道所述新型冠狀病毒特免血漿治療工作為公司控股股東中國生物技術股份有限公司與相關機構合作開展。
二、公司的主營業務為血液製品的研發、生產和銷售,相關報道提及的新型冠狀病毒特免血漿療法屬於醫療技術,目前不納入藥品管理,不屬於公司主營業務範疇。公司下屬子公司僅為上述血漿療法提供設備及技術等支持,相關工作不會對公司的產品結構和主營業務產生影響。相關報道提及的新型冠狀病毒特免球蛋白目前正處於研發初期,後續研發情況存在不確定性,公司將按照證券監管要求履行信息披露義務。
三、公司將積極履行社會責任,助力打贏疫情防控阻擊戰。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.